Design and synthesis of an orally active GPIIb/IIIa antagonist based on a phenylpiperazine scaffold

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 12, 1998, Pages 1531-1536

  Van Maarseveen, Jan H ^a   Den Hartog, Jack A J ^a   Tipker, Koos ^a   Reinders, Jan Hendrik ^a   Brakkee, Joost ^a   Schön, Uwe ^b   Kehrbach, Wolfgang ^b   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Antagonists; Anticoagulants; Isosteres; Molecular modelling mechanics

Indexed keywords

4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PIPERAZINE DERIVATIVE; RO 43 8857; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CHEEK POUCH; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CRICETINAE; DRUG DESIGN; FIBRINOLYTIC AGENTS; GUINEA PIGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

ANIMALIA; CRICETINAE; THROMBUS;

EID: 0032537620     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00257-1     Document Type: Article

References (14)

1. 1 Relevant reviews: (a) Zablocki, J.A.; Rao, S.N.; Baron, D.; Flynn, D.; Nicholson, N.S.; Feigen, L.P. Curr. Pharm. Design. 1995, 1, 533.
2. (b) Mousa, S.A.; Cheresh, D.A. Drug Disc. Today 1997, 2, 187.
3. 2 Ku, T.W.; Ali, F.E.; Barton, L.S.; Bean, J.W.; Bondinell, W.E.; Burgess, J.L.; Callahan, J.F.; Calvo, R..; Chen, L.; Eggleston, D.S.; Gleason, J.G.; Huffman, W.F.; Hwang, S.M.; Jakas, D.R.; Karash, C.B.; Keenan, R.M.; Kopple, K.D.; Miller, W.H.; Newlander, K.A.; Nichols, A.; Parker, M.F.; Peishoff, C.E.; Samanen, J.M.; Uzinskas, I.; Venslavsky, J.W.; J. Am. Chem. Soc. 1993, 115, 8861.
4. 3 Wagner, G.; Horn, H.; Richter, P.; Vieweg, H.; Lischke, I.; Kazmirowski, H-G. Pharmazie 1981, 36, 597.
5. 4 Eldred, C.D.; Evans, B.; Hindley, S.; Judkins, B.D.; Kelly, H.A.; Kitchin, J.; Lumley, P.; Porter, B.; Ross, B.C.; Smith, K.J.; Taylor, N.R.; Wheatcroft, J.R. J. Med. Chem. 1994, 37, 3882.
6. 5 Alig, L.; Edenhofer, A.; Hadváry, P.; Hürzeler, M.; Knopp, D.; Müller, M.; Steiner, B.; Trzeciak, A.; Weller, T. J. Med. Chem. 1992, 35, 4393.
7. 2)=NH method. After protection of the amidine moiety with a Boc group and catalytic removal of the Z protective group 17 was obtained.
8. 7 The phenylpiperazines 19-20 were synthesized by heating of methyl-m-aminophenylacetate and ethyl-p-amino phenylacetate, respectively, with bis-2-chloroethylamine hydrochloride in chlorobenzene at reflux for 14h. The phenylpiperazines 18, 22 and 23 are commercially available. 24 was obtained after heating of 3-(4-aminophenyl)-propionic acid tert-butyl ester (obtained after catalytic hydrogenation of E-3-(4-nitrophenyl)-propenoic acid tert-butyl ester) with bis-2-chloroethylamine hydrochloride in chlorobenzene at reflux for 14h.
9. 8 Wagner, G.; Voigt, B.; Vieweg, H. Pharmazie 1984, 39, 226.
10. +), found: 354,4028.
11. 10 Kouns, W.C.; Kirchhofer, D.; Hadváry, P.; Edenhofer, A.; Weller, T.; Pfenninger, G.; Baumgartner, H.R.; Jennings, L.K.; Steiner, B. Blood 1992, 80, 2539.
12. 11 Dijkstra, G.D.H. Recl.Trav. Chim. Pays-Bas 1993, 112, 151.
13. 12 Born, J.V.R. Nature 1962, 194, 927.
14. 13 Sim, A.K.; McCraw, A.P.; Cleland, M.E.; Lardy, C.; Guerrier, D. Thromb. Haemostas. 1993, 69, 670.